Diagnostic accuracy of Fusobacterium nucleatum IgA and IgG ELISA test in colorectal cancer
- PMID: 33452405
- PMCID: PMC7811007
- DOI: 10.1038/s41598-021-81171-1
Diagnostic accuracy of Fusobacterium nucleatum IgA and IgG ELISA test in colorectal cancer
Abstract
The colorectal cancer is a serious health problem. The diagnosis of the disease mostly relies on an invasive procedure. A non-invasive diagnostic test such as an immunoassay, may facilitate diagnosis of colorectal cancer. The purpose of the study was to evaluate the use of antibodies against Fusobacterium nucleatum in the diagnosis of colorectal cancer (CRC). Totally 78 patients in three groups were included in the study. F. nucleatum in the tissues was detected using quantitative polymerase chain reaction assay. F. nucleatum IgA and IgG were measured using enzyme linked immunosorbent assay. F. nucleatum was detected in 86.7% and 73.1% cases of CRC and precancerous-benign colon disease (P-BCD), respectively. The OD values from F. nucleatum IgA and IgG ELISA tests were higher in CRC group compared with healthy individuals. The sensitivity of IgA ELISA test varied between 31.8 and 95.5% depending on the chosen cut-off values. The positivity rate of antibodies in patients with high amount of F. nucleatum in tissue was significantly greater than in the negative group. The F. nucleatum IgA and IgG antibodies in CRC were higher than the ones in healthy controls but the discriminative ability of the ELISA test was not adequate to be considered as a diagnostic tool.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.JAMA Oncol. 2015 Aug;1(5):653-61. doi: 10.1001/jamaoncol.2015.1377. JAMA Oncol. 2015. PMID: 26181352 Free PMC article.
-
Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1891-1899. doi: 10.1007/s10096-019-03649-1. Epub 2019 Jul 31. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31367996 Free PMC article.
-
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.Gastroenterology. 2017 Mar;152(4):851-866.e24. doi: 10.1053/j.gastro.2016.11.018. Epub 2016 Nov 19. Gastroenterology. 2017. PMID: 27876571 Free PMC article.
-
Fusobacterium nucleatum in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis.Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):539-548. doi: 10.1158/1055-9965.EPI-18-1295. Epub 2020 Jan 8. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 31915144
-
Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta-analysis.Cancer Med. 2019 Feb;8(2):480-491. doi: 10.1002/cam4.1850. Epub 2019 Jan 12. Cancer Med. 2019. PMID: 30636375 Free PMC article.
Cited by
-
Fusobacterium nucleatum and cancer.Periodontol 2000. 2022 Jun;89(1):166-180. doi: 10.1111/prd.12426. Epub 2022 Mar 4. Periodontol 2000. 2022. PMID: 35244982 Free PMC article. Review.
-
Gut microbiota dysbiosis and associated immune response in systemic lupus erythematosus: impact of disease and treatment.Gut Pathog. 2025 Feb 18;17(1):10. doi: 10.1186/s13099-025-00683-7. Gut Pathog. 2025. PMID: 39966979 Free PMC article.
-
LncRNA SNHG4 promotes malignant biological behaviors and immune escape of colorectal cancer cells by regulating the miR-144-3p/MET axis.Am J Transl Res. 2021 Oct 15;13(10):11144-11161. eCollection 2021. Am J Transl Res. 2021. PMID: 34786048 Free PMC article.
-
Fusobacterium nucleatum Acts as a Pro-carcinogenic Bacterium in Colorectal Cancer: From Association to Causality.Front Cell Dev Biol. 2021 Aug 20;9:710165. doi: 10.3389/fcell.2021.710165. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34490259 Free PMC article. Review.
-
Application of Fusobacterium nucleatum as a biomarker in gastrointestinal malignancies.World J Gastrointest Oncol. 2024 Jun 15;16(6):2271-2283. doi: 10.4251/wjgo.v16.i6.2271. World J Gastrointest Oncol. 2024. PMID: 38994170 Free PMC article.
References
-
- Shirazi, M. S. R., Al-Alo, K. Z. K., Al-Yasiri, M. H., Lateef, Z. M. & Ghasemian, A. Microbiome dysbiosis and predominant bacterial species as human cancer biomarkers. J. Gastrointest. Cancer. (2019). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous